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Endometrial hyperplasia is an abnormal diffuse or local proliferation of glandular and stromal constituents of 
endometrium with predominant affection of glandular structures. According to literature data, frequency of this 
abnormality is 15-50% among all the gynecological disorders. Women with endometrial hyperplasia have an elevated 
risk of endometrial carcinoma. Investigation sampling comprised 1501 women: 253 patients had endometrial 
hyperplasia and 981 women were from the control group. In the group under study, it was performed typing seven 
molecular and genetic markers: ESR1 (rs1884051), BSX (rs6589964), CD40LG (rs5930973), FTO (rs9939609), PLCL1 
(rs12617311), INHBA (rs1079866), UGT2B4 (rs13111134). Article concerns data of the bio-informational analysis of 
polymorphic options of genes at patients with endometrial hyperplasia and women in control group. There were 
determined that combination of four genetic variants rs12617311 with rs1079866 with rs13111134 and rs9939609 
(OR=0.73) is protective factor of endometrial hyperplasia, and combination genetic markers rs1884051  with rs6589964 
with rs5930973  and rs9939609 (OR=2.14) is risk factor for endometrial hyperplasia in the women of Russia Central 
Region. 
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INTRODUCTION.
Endometrial hyperplasia is a pre-cancerous, non-
physiological, non-invasive proliferation of the 
endometrium that results in increased volume of 
endometrial tissue with alterations of glandular 
architecture (shape and size) and endometrial gland 
to stroma ratio of greater than 1:1 (Krivoshei I.V. 
et al., 2015, Chandra V. et al., 2016,  Yuk J.-S. et 
al., 2016). Endometrial hyperplasia is defined as 
abnormal proliferation of the uterine endometrial 
glands (Ponomarenko I.V. et al., 2016a).  
Endometrial hyperplasia has a significant place in 
the structure of gynecological morbidity in women 
of reproductive age and is one of the most frequent 
causes of hospitalization in gynecology hospital 
(10% to 18%) (Byun J. M. et al., 2015, 
Ponomarenko I.V. et al., 2016b). Women with 
endometrial hyperplasia have an elevated risk of 
endometrial carcinoma, and like endometrial 
carcinoma (Chen Y-L et al., 2013,  Kadirogullari 
P. et al., 2015). Endometrial hyperplasia has been 
classified into 3 main types: simple hyperplasia, 
characterized by minimal endometrial glandular 
crowding and with low risk of progression to 
endometrial carcinoma; complex hyperplasia, 
characterized by greater endometrial glandular 
crowding and intermediate risk of progression; and 
atypical hyperplasia, comprised of endometrium 
with complex glandular crowding and/or cytologic 
atypia and the greatest risk of endometrial 
carcinoma progression (Boyraz G.et al., 2016). The 
most common symptom of endometrial 
hyperplasia is abnormal uterine bleeding including, 
menorrhagia, intermenstrual bleeding, 
postmenopausal bleeding, and irregular bleeding 
when on hormone replacement therapy (Orbo A. et 
al., 2016). Now it is known that polymorphisms of 
several genes are important in the formation of 
disposition to the development of endometrial 
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hyperplasia. However, the results of studies on the 
role of candidate genes in the formation of 
endometrial hyperplasia are controversial in 
different populations. 
 
MATERIALS AND METHODS.  
There was performed analysis of the observation 
data for 1501 persons: 520 patients with 
endometrial hyperplasia and 981 females from the 
reference panel. The patients and reference panels 
included Russian women, natives of the Central 
region of Russia and not having family ties among 
themselves. Clinical laboratory examination of the 
patients was performed at the gynecology 
department of the perinatal center of the Bishop 
Ioasaf Belgorod Regional Clinical Hospital. The 
examination of patients was carried out on the 
basis of the gynecology department of the perinatal 
centre of Belgorod region clinical hospital of 
Josaphat the Sanctifier. All the patients with 
endometrial hyperplasia and the control group 
samples had typing of seven molecular and genetic 
markers:  
 ESR1 c.1096+17636G>A (rs1884051), BSX 
g.122870683A>C (rs6589964), CD40LG c.157-277G>A 
(rs5930973), FTO c.46-23525T>A (rs9939609), PLCL1 
g.198767841G>A (rs12617311), INHBA g.41430495C>G 
(rs1079866), UGT2B4 c.594+346C>T (rs13111134). 
Venous blood samples with the volume of 8-9 ml 
drawn from the ulnar vein of the proband were 
used as a test material. Genomic DNA extraction 
from peripheral blood was performed by the 
standard method of phenol-chloroform extraction 
from frozen venous blood samples (Miller S. A. et 
al., 1988). Analysis of the examined loci was 
carried out by the method of polymerase chain 
reaction of DNA synthesis with use of 
oligonucleotide primers and probes. Estimation of 
role of the studied genetic variants combinations in 
contraction of endometrial hyperplasia is 
performed using the software APSampler using 
Markov chains Monte Carlo technique and 
Bayesian distribution-free statistics. In order to 
minimize type I errors, Bonferroni correction 
(рcor) and permutation test (рperm) were used for 
multiple comparisons (Favorov, A. V. et al., 2005).  
 
RESULTS AND DISCUSSION.  
After examination of 520 women with endometrial 
hyperplasia and 981 women from the control 
group, it was determined, that the control group is 
completely commeasurable with sampling of cases 
with genital endometriosis by gender, age, 
nationality and place of birth, and by height and 
weight (р>0.05). Main characteristics of the 
studied groups are given in the Table 1. 
Table 1: Characteristics of the subjects from the case 
and control groups. 
Characteristics Cases Controls 
Total 520 981 
Age, yrs  41.78 ±10.04 40.73 ±8.60 
Weight, kg  61.5±2.9 64.3±3.5  
Height, cm  163.7±3.1 167.4±3.8 
 
Examination of alleles concentration of genes 
polymorphic markers under study showed that for 
all the examined locuses in the group of patients 
with genital endometriosis and in population 
sampling, empiric genotype distribution 
corresponded to the expected one at Hardy-
Weinberg equilibrium (p>0.05) (Table 2). 
Table 2: Summary information about the studied 
polymorphisms. 
Polymorphism Studied groups Minor allele MAF (%) HWE 
χ2 p 
ESR1 c.1096+17636G>A (rs1884051) Case G 0.39 3,25 >0.05 
ESR1 c.1096+17636G>A (rs1884051) Control G 0.35 2,96 >0.05 
BSX g.122870683A>C(rs6589964) Case A 52.23 2.42 >0.05 
BSX g.122870683A>C(rs6589964) Control A 49.25 2.49 >0.05 
CD40LG c.157-277G>A (rs5930973) Case A 0.19 0.89 >0.05 
CD40LG c.157-277G>A (rs5930973) Control A 0.15 0.97 >0.05 
FTO c.46-23525T>A (rs9939609) Case A 0.49 0.40 >0.05 
FTO c.46-23525T>A (rs9939609) Control A 0.46 0.32 >0.05 
PLCL1 g.198767841G>A (rs12617311) Case A 0.39 0.35 >0.05 
PLCL1 g.198767841G>A (rs12617311) Control A 0.35 0.43 >0.05 
INHBA g.41430495C>G (rs1079866) Case С 0.21 1,12 >0.05 
INHBA g.41430495C>G (rs1079866) Control С 0.19 1,25 >0.05 
UGT2B4 c.594+346 G>A (rs13111134) Case A 0.31 1,67 >0.05 
UGT2B4 c.594+346 G>A (rs13111134) Control A 0.27 1,59 >0.05 
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Notes: MAF, minor allele frequency; Hardy – 
Weinberg equilibrium. P values were calculated 
using the χ2 test. 
While using bio-informational approaches, is was 
determined that combination of four genetic 
variants G ESR1 (rs1884051)  with C BSX 
(rs6589964) with A CD40LG (rs5930973)  and A 
FTO (rs9939609) in the group of cases with 
endometrial hyperplasia (5.03%) is much more 
often (2.2 times more) than in the control group 
(2.29%, pbonf=0.04, pperm=0.008). These data 
testify about a great contribution of combination of 
polymorphicс genes variants rs1884051 and 
rs6589964 and rs5930973 and rs9939609 to 
endometrial hyperplasia (OR=2.14, CI 1.19-3.86). 
The estrogen receptor 1 (ESR1) gene encodes an 
estrogen receptor, a ligand-activated transcription 
factor composed of several domains important for 
hormone binding, DNA binding, and activation of 
transcription. The protein localizes to the nucleus 
where it may form a homodimer or a heterodimer 
with estrogen receptor 2 (Hewitt S. C. et al., 2016). 
Estrogen and its receptors are essential for sexual 
development and reproductive function, but also 
play a role in other tissues such as bone. Estrogen 
receptors are also involved in pathological 
processes including breast cancer, endometrial 
cancer, and osteoporosis (Jeselsohn R. et al., 2015, 
Okur H. S. et al., 2016). Alternative promoter 
usage and alternative splicing result in dozens of 
transcript variants, but the full-length nature of 
many of these variants has not been determined 
(Hewitt S. C. et al., 2016). 
DNA binding protein BSX that function as 
transcriptional activator. Is essentiel for normal 
postnatal growth and nursing. Is an essential factor 
for neuronal neuropeptide Y and agoutirelated 
peptide function and locomotory behavior in the 
control of energy balance (Lee B. et al., 2013). 
The Fat mass and obesity associated (FTO) gene is 
a nuclear protein of the AlkB  elated non-haem 
iron and 2-oxoglutarate-dependent oxygenase 
superfamily but the exact physiological function of 
this gene is not known (Qi Q. et al., 2014). Other 
non-heme iron enzymes function to reverse 
alkylated DNA and RNA damage by oxidative 
demethylation. Studies in mice and humans 
indicate a role in nervous and cardiovascular 
systems and a strong association with body mass 
index, obesity risk, and type 2 diabetes (Harbron J. 
et al., 2014, Loos R. J.F. et al., 2014,). 
It has been discovered that combination of genetic 
variants G rs12617311 (PLCL1) with G rs1079866 
(INHBA) with A rs13111134 (UGT2B4) and A 
rs9939609 FTO occur in 20.70% of sick women, 
respectively, which is 1.27 times lower than that 
occur in control group (26.31%, pbonf=0.04, 
pperm=0.008). When there are these combination 
of polymorphic markers, pathology risk of 
endometrial hyperplasia is significantly lower 
(OR=0.73, CI 0.56-0.94). 
Phospholipase C-like 1 (PLCL1) is a protein-
coding gene involved in an inositol  phospholipid-
based intracellular signaling cascade. Shows no 
PLC activity to phosphatidylinositol 4,5-
bisphosphate and phosphatidylinositol. Component 
in the phospho-dependent endocytosis process of 
GABA A receptor (By similarity). Regulates the 
turnover of receptors and thus contributes to the 
maintenance of GABA-mediated synaptic 
inhibition (Liu Y.-Z. et al., 2008). 
The inhibin beta A (INHBA) subunit joins the 
alpha subunit to form a pituitary FSH secretion 
inhibitor. Inhibin has been shown to regulate 
gonadal stromal cell proliferation negatively and to 
have tumor-suppressor activity. In addition, serum 
levels of inhibin have been shown to reflect the 
size of granulosa-cell tumors and can therefore be 
used as a marker for primary as well as recurrent 
disease. Because expression in gonadal and various 
extragonadal tissues may vary severalfold in a 
tissue-specific fashion, it is proposed that inhibin 
may be both a growth/differentiation factor and a 
hormone. Furthermore, the beta A subunit forms a 
homodimer, activin A, and also joins with a beta B 
subunit to form a heterodimer, activin AB, both of 
which stimulate FSH secretion (Tournier I.  et al., 
2014). 
Glycosyltransferase 2 family, polypeptide B4 
(UGT2B4) is of major importance in the 
conjugation and subsequent elimination of 
potentially toxic xenobiotics and endogenous 
compounds. This isozyme is active on 
polyhydroxylated estrogens (such as estriol, 4-
hydroxyestrone and 2-hydroxyestriol) and 
xenobiotics (such as 4-methylumbelliferone, 1-
naphthol, 4-nitrophenol, 2-aminophenol, 4-
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hydroxybiphenyl and menthol) (Sun C. et al., 
2011). 
CONCLUSION.  
Therefore the results of work allow making a 
conclusion that combination of four genetic 
variants rs12617311 with rs1079866 with 
rs13111134 and rs9939609 (OR=0.73) is 
protective factor of endometrial hyperplasia, and 
combination genetic markers rs1884051 with 
rs6589964 with rs5930973 and rs9939609 
(OR=2.14) is risk factor for endometrial 
hyperplasia in the women of Russia Central 
Region. 
 
Summary.  Genetic polymorphisms rs12617311, 
rs1079866, rs13111134, rs9939609, rs1884051, 
rs6589964 and rs5930973 are associated with the 
development of endometrial hyperplasia. 
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